San Francisco, California
London, United Kingdom
Jennifer Good, President and CEO
Thomas Sciascia, M.D., Chief Medical Officer
Presentation: 4 pm Networking: 5 pm
Trevi Therapeutics, Inc. is a New Haven based drug development company founded in 2011 and focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. Specifically the Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itch that afflicts about 70 percent of the 450,000 patients on dialysis and has been linked with increased mortality. Nalbuphine ER is an oral extended release opioid with a unique opioid receptor dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus. Because of Nalbuphine ER’s centrally acting dual mechanism of action, the company believes it can have broad utility in treating chronic pruritus and is actively pursuing a second indication in dermatology.
Trevi Therapeutics raised $10 million in Series A cash from the venture arm of TPG.
November 6, 2013
Presentation 4 pm Networking 5 pm
Venue: BioHaven @ Yale School of Medicine, Anlyan Center, 300 Cedar Street, New Haven
Lisa Kurek, Program Director, SBIR Impact NYC; Managing Partner of BBC Entrepreneurial Training and Consulting
Merrie London, SBIR Manager at Connecticut Innovations
Thank you to our sponsors.
When & Where
CURE is the bioscience cluster of Connecticut, a diverse network of small and large life and health care sciences companies, universities, scientists, educators, students, entrepreneurs, mentors, business experts, and investors. Together we cultivate entrepreneurship, build bioscience companies, and collaborate to ensure a sustainable, high-value bioscience and healthcare community that improves our quality of life and keeps the Connecticut economy strong.